# US 2001/0024813 A1 · Human dendriac and brainiac-3

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024813 A1
- Document ID: US20010024813A1
- Status: Published application
- Kind: A1
- Application number: 09/739,451
- Filed: 2000-12-19
- Published: 2001-09-27
- Earliest claimed: 1997-12-18
- Inventors: Reinhard Ebner; Daniel R. Soppet; Gregory A. Endress; Kimberly A. Florence; Guo-Liang Yu; Steven M. Ruben; Craig A. Rosen
- Web page: https://patentgrep.com/patent/US20010024813A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to novel Dendriac and novel Brainiac-3 polypeptides which are members of the Brainiac family. In particular, isolated nucleic acid molecules are provided encoding the human Dendriac and Brainiac-3 polypeptides. Dendriac and Brainiac-3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Dendriac and Brainiac-3 activities. Also provided are diagnostic methods for detecting immune and nervous system-related disorders and therapeutic methods for treating immune and nervous system-related disorders.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
(a) a nucleotide sequence encoding the Dendriac polypeptide having the complete amino acid sequence in SEQ ID NO:2 and SEQ ID NO:10 (i.e., positions −25 to 294 of SEQ ID NO:2 and SEQ ID NO:10);
(b) a nucleotide sequence encoding the Dendriac polypeptide having the complete amino acid sequence in SEQ ID NO:2 and SEQ ID NO: 10 excepting the N-terminal methionine (i.e., positions −24-294 of SEQ ID NO:2 and SEQ ID NO:10);
(c) a nucleotide sequence encoding the predicted mature Dendriac polypeptide having the amino acid sequence at positions 1-294 in SEQ ID NO:2 and SEQ ID NO: 10;
(d) a nucleotide sequence encoding the Dendriac polypeptide having the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 203056 and in ATCC Deposit No. 209056;
(e) a nucleotide sequence encoding the Dendriac polypeptide having the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in ATCC Deposit No. 203056 and in ATCC Deposit No. 209056;
(f) a nucleotide sequence encoding the mature Dendriac polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 203056 and in ATCC Deposit No. 209056; and
(g) a nucleotide sequence encoding the Brainiac-3 polypeptide having the complete amino acid sequence in SEQ ID NO:4 and SEQ ID NO:12 (i.e., positions −28 to 324 of SEQ ID NO:4);
(h) a nucleotide sequence encoding the Brainiac-3 polypeptide having the complete amino acid sequence in SEQ ID NO:4 and SEQ ID NO:12 excepting the N-terminal methionine (i.e., positions −27-324 of SEQ ID NO:4 and SEQ ID NO:12);
(i) a nucleotide sequence encoding the predicted mature Brainiac-3 polypeptide having the amino acid sequence at positions 1-324 in SEQ ID NO:4 and SEQ ID NO:12;
(j) a nucleotide sequence encoding the Brainiac-3 polypeptide having the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 203451 and in ATCC Deposit No. 209463;
(k) a nucleotide sequence encoding the Brainiac-3 polypeptide having the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in ATCC Deposit No. 203451 and in ATCC Deposit No. 209463;
(l) a nucleotide sequence encoding the mature Brainiac-3 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 203451 and in ATCC Deposit No. 209463; and
(m) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k) or (l), above.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1 wherein said polynucleotide has the complete nucleotide sequence in FIGS. 1A, 1B, and 1C (SEQ ID NO:1), in SEQ ID NO:9, in FIGS. 2A and 2B (SEQ ID NO:3) or in SEQ ID NO: 11.

### Claim 3 (depends on 1)

The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in FIGS. 1A, 1B, and 1C (SEQ ID NO: 1) or in SEQ ID NO:9 encoding the Dendriac polypeptide having the amino acid sequence in positions −25 to 294 of SEQ ID NO:2 and SEQ ID NO:10.

### Claim 4 (depends on 1)

The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in FIGS. 2A and 2B (SEQ ID NO:3) or in SEQ ID NO: 11 encoding the Brainiac-3 polypeptide having the amino acid sequence in positions −28 to 324 of SEQ ID NO:4 and SEQ ID NO:12.

### Claim 5 (depends on 1)

The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in FIGS. 1A, 1B, and 1C (SEQ ID NO:1) or SEQ ID NO:9 encoding the Dendriac polypeptide having the amino acid sequence in positions −24 to 294 of SEQ ID NO:2 and SEQ ID NO:10.

### Claim 6 (depends on 1)

The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in FIGS. 2A and 2B (SEQ ID NO:3) or SEQ ID NO:11 encoding the Brainiac-3 polypeptide having the amino acid sequence in positions −27 to 324 of SEQ ID NO:4 and SEQ ID NO:12.

### Claim 7 (depends on 1)

The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in FIGS. 1A, 1B, and 1C (SEQ ID NO: 1) or SEQ ID NO:9 encoding the mature form of the Dendriac polypeptide having the amino acid sequence from about 1 to about 294 in SEQ ID NO:2 and SEQ ID NO:10.

### Claim 8 (depends on 1)

The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence in FIGS. 2A and 2B (SEQ ID NO:3) encoding the mature form of the Brainiac-3 polypeptide having the amino acid sequence from about 1 to about 324 in SEQ ID NO:4 and SEQ ID NO: 12.

### Claim 9

An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
(a) a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of residues n1-294 of SEQ ID NO:2 and SEQ ID NO:10, where n1 is an integer in the range of −25 through 56;
(b) a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of residues −25-m1 of SEQ ID NO:2 and SEQ ID NO: 10, where m1 is an integer in the range of 292 through 294;
(c) a nucleotide sequence encoding a polypeptide having the amino acid sequence consisting of residues n1-m1 of SEQ ID NO:2 and SEQ ID NO:10, where n and m are integers as defined respectively in (a) and (b) above;
(d) a nucleotide sequence encoding a polypeptide consisting of a portion of the complete Dendriac amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Nos. 203056 and 209627 wherein said portion excludes from 1 to about 81 amino acids from the amino terminus of said complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Nos. 203056 and 209627;
(e) a nucleotide sequence encoding a polypeptide consisting of a portion of the complete Dendriac amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Nos. 203056 and 209627 wherein said portion excludes from 1 to about 3 amino acids from the carboxy terminus of said complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Nos. 203056 and 209627;
(f) a nucleotide sequence encoding a polypeptide consisting of a portion of the complete Dendriac amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Nos. 203056 and 209627 wherein said portion include a combination of any of the amino terminal and carboxy terminal deletions in (d) and (e), above;
(g) a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of residues n2-324 of SEQ ID NO:4 and SEQ ID NO:12, where n2 is an integer in the range of −28 through 80;
(h) a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of residues −28-m2 of SEQ ID NO:4 and SEQ ID NO:12, where m2 is an integer in the range of 316 through 324;
(i) a nucleotide sequence encoding a polypeptide having the amino acid sequence consisting of residues n2-m2 of SEQ ID NO:4 and SEQ ID NO: 12, where n2 and m2 are integers as defined respectively in (a) through (d) above;
a nucleotide sequence encoding a polypeptide consisting of a portion of the complete Brainiac-3 amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Nos. 203451 and 209463 wherein said portion excludes from 1 to about 108 amino acids from the amino terminus of said complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Nos. 203451 and 209463;
(k) a nucleotide sequence encoding a polypeptide consisting of a portion of the complete Brainiac-3 amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Nos. 203451 and 209463 wherein said portion excludes from 1 to about 8 amino acids from the carboxy terminus of said complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Nos. 203451 and 209463; and
(l) a nucleotide sequence encoding a polypeptide consisting of a portion of the complete Brainiac-3 amino acid sequence encoded by the cDNA clone contained in ATCC Deposit Nos. 203451 and 209463 wherein said portion include a combination of any of the amino terminal and carboxy terminal deletions in (d) and (e), above.

### Claim 10 (depends on 1)

The nucleic acid molecule of claim 1 wherein said polynucleotide has the complete nucleotide sequence of the cDNA clone contained in ATCC Deposit No. 203056, in ATCC Deposit No. 209627, in ATCC Deposit No. 203451 or in ATCC Deposit No. 209463.

### Claim 11 (depends on 1)

The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding the Dendriac or Brainiac-3 polypeptides having the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clones contained in ATCC Deposit No. 203056, in ATCC Deposit No. 209627, in ATCC Deposit No. 203451 or in ATCC Deposit No. 209463.

### Claim 12 (depends on 1)

The nucleic acid molecule of claim 1 wherein said polynucleotide has the nucleotide sequence encoding the mature form of the Dendriac or Brainiac-3 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 203056, in ATCC Deposit No. 209627, in ATCC Deposit No. 203451 or in ATCC Deposit No. 209463.

### Claim 13 (depends on 1)

An isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) or (m) of claim 1 wherein said polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.

### Claim 14 (depends on 1)

An isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of a Dendriac or Brainiac-3 polypeptide having an amino acid sequence in (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) or (m) of claim 1.

### Claim 15 (depends on 14)

The isolated nucleic acid molecule of claim 14, which encodes an epitope-bearing portion of a Dendriac polypeptide wherein the amino acid sequence of said portion is selected from the group of sequences in SEQ ID NO:2 and SEQ ID NO:10 consisting of: about Leu-30 to about His-38; from about His-50 to about Ala-59; from about Trp-64 to about Trp-70; from about Met-208 to about Val-213; from about Lys-224 to about Asp-230; from about Ile-246 to about Leu-252; and from about Gly-273 to about Glu-278.

### Claim 16 (depends on 14)

The isolated nucleic acid molecule of claim 14, which encodes an epitope-bearing portion of a Brainiac-3 polypeptide wherein the amino acid sequence of said portion is selected from the group of sequences in SEQ ID NO:4 and SEQ ID NO:12 consisting of: about Lys-1 to about Ser-12; about Pro-16 to about Pro-25; about Leu-36 to about Arg-41; about Pro-58 to about Asp-64; about Ser-73 to about Ile-84; about Thr-87 to about Pro-97; about Leu-161 to about Val-167; about Asp-179 to about Gln-185; about Leu-197 to about Lys-203; about Gly-275 to about Asp-284; and Arg-296 to about Glu-301.

### Claim 17 (depends on 1)

A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector.

### Claim 18 (depends on 17)

A recombinant vector produced by the method of claim 17.

### Claim 19 (depends on 18)

A method of making a recombinant host cell comprising introducing the recombinant vector of claim 18 into a host cell.

### Claim 20 (depends on 19)

A recombinant host cell produced by the method of claim 19.

### Claim 21 (depends on 20)

A recombinant method for producing a Dendriac or Brainiac-3 polypeptide, comprising culturing the recombinant host cell of claim 20 under conditions such that said polypeptide is expressed and recovering said polypeptide.

### Claim 22

An isolated Dendriac and Brainiac-3 polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
(a) the amino acid sequence of the full-length Dendriac polypeptide having the complete amino acid sequence shown in SEQ ID NO:2 and SEQ ID NO:10 (i.e., positions −25 through 294 of SEQ ID NO:2 and SEQ ID NO:10);
(b) the amino acid sequence of the full-length Dendriac polypeptide having the complete amino acid sequence shown in SEQ ID NO:2 and SEQ ID NO:10 excepting the N-terminal methionine (i.e., positions −24-294 of SEQ ID NO:2 and SEQ ID NO:10);
(c) the amino acid sequence of the predicted mature Dendriac polypeptide having the amino acid sequence at positions 1-294 in SEQ ID NO:2 and SEQ ID NO:10;
(d) the complete amino acid sequence encoded by the cDNA clone contained in the ATCC Deposit No. 203056 and in ATCC Deposit No. 209627;
(e) the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in the ATCC Deposit No. 203056 and in ATCC Deposit No. 209627;
(f) the complete amino acid sequence of the predicted mature Dendriac polypeptide encoded by the cDNA clone contained in the ATCC Deposit No. 203056 and in ATCC Deposit No. 209627;
(g) the amino acid sequence of the full-length Brainiac-3 polypeptide having the complete amino acid sequence shown in SEQ ID NO:4 and SEQ ID NO:12 (i.e., positions −28 through 324 of SEQ ID NO:4 and SEQ ID NO:12);
(h) the amino acid sequence of the full-length Brainiac-3 polypeptide having the complete amino acid sequence shown in SEQ ID NO:4 and SEQ ID NO:12 excepting the N-terminal methionine (i.e., positions −27 through 324 of SEQ ID NO:4 and SEQ ID NO:12);
(i) the amino acid sequence of the predicted mature Brainiac-3 polypeptide having the amino acid sequence at positions 1 through 324 in SEQ ID NO:4 and SEQ ID NO:12;
(j) the complete amino acid sequence encoded by the cDNA clone contained in the ATCC Deposit No. 203451 and in ATCC Deposit No. 209463;
(k) the complete amino acid sequence excepting the N-terminal methionine encoded by the cDNA clone contained in the ATCC Deposit No. 203451 and in ATCC Deposit No. 209463; and
(l) the complete amino acid sequence of the predicted mature Brainiac-3 polypeptide encoded by the cDNA clone contained in the ATCC Deposit No. 203451 and in ATCC Deposit No. 209463.

### Claim 23

An isolated polypeptide comprising an epitope-bearing portion of the Dendriac protein, wherein said portion is selected from the group consisting of: a polypeptide comprising amino acid residues from about Leu-30 to about His-38 of SEQ ID NO:2 and SEQ ID NO:10; a polypeptide comprising amino acid residues from about His-50 to about Ala-59 of SEQ ID NO:2 and SEQ ID NO:10; a polypeptide comprising amino acid residues from about Trp-64 to about Trp-70 of SEQ ID NO:2 and SEQ ID NO:10; a polypeptide comprising amino acid residues from about Met-208 to about Val-213 of SEQ ID NO:2 and SEQ ID NO:10; a polypeptide comprising amino acid residues from about Lys-224 to about Asp-230 of SEQ ID NO:2 and SEQ ID NO: 10; a polypeptide comprising amino acid residues from about Ile-246 to about Leu-252 of SEQ ID NO:2 and SEQ ID NO:10; and a polypeptide comprising amino acid residues from about Gly-273 to about Glu-278 of SEQ ID NO:2 and SEQ ID NO:10.

### Claim 24

An isolated polypeptide comprising an epitope-bearing portion of the Brainiac-3 protein, wherein said portion is selected from the group consisting of: a polypeptide comprising amino acid residues from about Lys-l to about Ser-12 in SEQ ID NO:4 and SEQ ID NO:12; a polypeptide comprising amino acid residues from about Pro-16 to about Pro-25 in SEQ ID NO:4 and SEQ ID NO:12; a polypeptide comprising amino acid residues from about Leu-36 to about Arg-41 in SEQ ID NO:4 and SEQ ID NO:12; a polypeptide comprising amino acid residues from about Pro-58 to about Asp-64 in SEQ ID NO:4 and SEQ ID NO:12; a polypeptide comprising amino acid residues from about Ser-73 to about Ile-84 in SEQ ID NO:4 and SEQ ID NO: 12; a polypeptide comprising amino acid residues from about Thr-87 to about Pro-97 in SEQ ID NO:4 and SEQ ID NO:12; a polypeptide comprising amino acid residues from about Leu-161 to about Val-167 in SEQ ID NO:4 and SEQ ID NO:12; a polypeptide comprising amino acid residues from about Asp-179 to about Gln-185 in SEQ ID NO:4 and SEQ ID NO:12; a polypeptide comprising amino acid residues from about Leu-197 to about Lys-203 in SEQ ID NO:4 and SEQ ID NO:12; a polypeptide comprising amino acid residues from about Gly-275 to about Asp-284 in SEQ ID NO:4 and SEQ ID NO:12; and a polypeptide comprising amino acid residues from about Arg-296 to about Glu-301 in SEQ ID NO:4 and SEQ ID NO:12.

### Claim 25 (depends on 22)

An isolated antibody that binds specifically to a Dendriac or Brainiac-3 polypeptide of claim 22.

### Claim 26

An isolated nucleic acid molecule comprising a polynucleotide having a sequence at least 95% identical to a sequence selected from the group consisting of:
(a) the nucleotide sequence of SEQ ID NO:6;
(b) the nucleotide sequence of SEQ ID NO:7;
(c) the nucleotide sequence of SEQ ID NO:8;
(d) the nucleotide sequence of a portion of the sequence shown in FIGS. 2A and 2B (SEQ ID NO:3) wherein said portion comprises at least 50 contiguous nucleotides from nucleotide 150 to 650;
(e) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), and (d) above.
